Holen Sie sich die Stockscreener-App
8.8326
1.07%
-0.0274
Schlusskurs vom Vortag:
$8.86
Offen:
$8.84
24-Stunden-Volumen:
259.92K
Relative Volume:
0.47
Marktkapitalisierung:
$453.56M
Einnahmen:
$57.94M
Nettoeinkommen (Verlust:
$-151.18M
KGV:
-3.1415
EPS:
-2.8116
Netto-Cashflow:
$-86.56M
1W Leistung:
-3.89%
1M Leistung:
+1.21%
6M Leistung:
-2.18%
1J Leistung:
+6.24%
1-Tages-Spanne:
$8.729
$9.075
1-Wochen-Bereich:
$8.75
$9.365
52-Wochen-Spanne:
$7.73
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corp Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
8.835 | 454.85M | 57.94M | -151.18M | -86.56M | -2.8116 |
VRTX
Vertex Pharmaceuticals Inc
|
515.13 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.23 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.83 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.30 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.42 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-04-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Oppenheimer | Outperform |
| 2021-05-26 | Eingeleitet | Citigroup | Buy |
| 2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
| 2018-04-05 | Bestätigt | Barclays | Overweight |
| 2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2017-09-29 | Bestätigt | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-12-21 | Eingeleitet | SunTrust | Buy |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-08-04 | Bestätigt | Barclays | Overweight |
| 2016-05-13 | Eingeleitet | Barclays | Overweight |
| 2016-02-19 | Bestätigt | Wedbush | Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corp Plc Aktie (PRTA) Neueste Nachrichten
HC Wainwright Issues Positive Estimate for Prothena Earnings - MarketBeat
Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise - Sahm
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - Yahoo Finance
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena: Q2 Earnings Snapshot - marketscreener.com
Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone - Stock Titan
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - marketscreener.com
FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4% - Stock Titan
Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena (NASDAQ:PRTA) Insider Anne Evans Kingston Sells 7,662 Shares of Stock - marketbeat.com
Prothena Corp PLC (PRTA) Chief Strategy Officer Anne Kingston Se - GuruFocus
Prothena to Report Second Quarter 2026 Financial Results on August 6 - Yahoo Finance
BlackRock (PRTA holder) discloses 6.9% beneficial stake in Prothena common stock - Stock Titan
Prothena Corp. Plc Revenue Breakdown – LSX:A1KAVV - TradingView
Rubric Capital Management LP Has $48.60 Million Position in Prothena Corporation plc $PRTA - marketbeat.com
Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday - marketbeat.com
PRTA|Prothena Corporation PLC|Price:8.720|Chg%:-0.030 - TradingKey
Prothena stock trades steady as Alzheimer portfolio advances and earnings show growing R&D investmen - Ad-hoc-news.de
Trading the Move, Not the Narrative: (PRTA) Edition - Stock Traders Daily
Michael John Isaacs Net Worth (2026) - GuruFocus
Prothena (PRTA) Price Target Increased by 37.50% to 16.83 - msn.com
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - Yahoo Finance
Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens - ad-hoc-news.de
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
PRTAProthena Corp Plc Options - Finviz
Price to sales forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA - TradingView
Price to book forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to EBITDA forward of Prothena Corp. Plc – MUN:0PT - TradingView
Enterprise value to revenue forward of Prothena Corp. Plc – MUN:0PT - TradingView
Prothena Corp, Parkinson antibody program draws attention for the stock - ad-hoc-news.de
Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA) - TradingView
Prothena Corp. Plc Actuals & Estimates (DUS:0PT) - TradingView
Prothena Corp. Plc Actuals & Estimates (SWB:0PT) - TradingView
PRTA Forecast — Price Target — Prediction for 2027 - TradingView
0PT Forecast — Price Target — Prediction for 2027 - TradingView
Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit - Moomoo
Prothena Corp plc strategy in focus, shares watched against biotech peers - AD HOC NEWS
Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prothena Corporation PLC (PRTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (PRTA) for Rule-Based Strategy - Stock Traders Daily
(PRTA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
PRTA Q1 2026 Earnings: Surprise EPS Beat Driven by Milestone Revenue, Stock Edges HigherDownward Estimate Revision - The Legal Advocate
(PRTA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Penbrook Management LLC's Prothena Corp PLC(PRTA) Holding History - GuruFocus
Prothena (NASDAQ: PRTA) investors approve board, KPMG and executive pay - Stock Titan
Finanzdaten der Prothena Corp Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prothena Corp Plc-Aktie (PRTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 10% Owner |
Aug 07 '26 |
Buy |
8.62 |
3,500 |
30,167 |
83,500 |
| Kingston Anne Evans | Chief Strategy Officer |
Jul 29 '26 |
Sale |
8.47 |
7,662 |
64,919 |
55,782 |
| Isaacs Michael John | General Counsel & Company Sec. |
Jul 29 '26 |
Sale |
8.47 |
8,386 |
71,055 |
35,745 |
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):